A phase I/II study of the selective phosphatidylinositol 3-kinase-delta (PI3Kδ) inhibitor, GS-1101 (CAL-101), with ofatumumab in patients with previously treated chronic lymphocytic leukemia (CLL).
Richard R. Furman(Cornell University), Langdon L. Miller(Gilead Sciences (United States)), Jeff P. Sharman(Willamette Valley Cancer Institute and Research Center), Nina D. Wagner‐Johnston(Sidney Kimmel Comprehensive Cancer Center), Steven Coutré(Georgetown University), Marshall T. Schreeder(Clearview Cancer Institute), John P. Leonard(New York University), Nathan Fowler(Repligen (United States)), Brian J. Lannutti(Fate Therapeutics (United States)), Jacqueline C. Barrientos(Mount Sinai Medical Center), Sven de Vos(University of California, Los Angeles), Thomas E. Boyd(University of Vermont), Thomas M. Jahn(Memorial Sloan Kettering Cancer Center), Dave Johnson, Ian W. Flinn(Tennessee Oncology), Ralph V. Boccia(Center for Cancer and Blood Disorders), Leanne Holes(Gilead Sciences (United States))
Cited by 24
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
|New England Journal of Medicine|2000|3k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k